All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
#EHA2024: Treatments for relapsed or refractory ALL
To update you on the exciting content presented at the European Hematology Association (EHA) 2024 Hybrid Congress, we have collated our social media coverage. Catch up with our live social media relating to the treatment of relapsed or refractory ALL, here.
CONGRESS | POSTER | #EHA2024 | Hai Yi explored a shortened period of f blinatumomab treatment and sequential allo-HSCT in R/R B-cell AL. CR rate was 86.1% (56/65) with 52 patients (60%) achieving MRD negative status. Grade 1 CRS detected in 52.3% (34/65) patients, but grade 2 or… pic.twitter.com/yNSjtSrqkB
— ALL Hub (@ALL_Hub_) June 17, 2024
CONGRESS | POSTER | #EHA2024 | Lihong An reports the long-term efficacy of combination treatment with CD19 and CD22 CAR T-cells in patients with relapsed B-ALL after allo-HCT. In 24 patients who completed therapy, 3- and 5-year OS and EFS were 79% and 54% and 75% and 50%,… pic.twitter.com/KMYAMPnTlK
— ALL Hub (@ALL_Hub_) June 17, 2024
CONGRESS #EHA2024 | Ibrahim Aldoss @cityofhope presents findings of the phase II portion of a phase I/II trial (NCT04984356) evaluating safety and efficacy of WU-CART-007 in pts with R/R T-ALL/LBL (N=13). Treatment-related AEs of Grade ≥3 occurred in 61.5% of pts, and CRS was… pic.twitter.com/V6SBHlClq4
— ALL Hub (@ALL_Hub_) June 14, 2024
CONGRESS #EHA2024 | Claire Roddie @drclaireroddie @ucl presents findings of the phase Ib/II FELIX study (NCT04404660) of Obecabtagene autoleucel in adult patients with R/R B-ALL. 12-month EFS was 49.5% with censoring for allo-SCT, while 12-month OS was 61.1% without censoring for… pic.twitter.com/ig9pAis5Za
— ALL Hub (@ALL_Hub_) June 14, 2024
CONGRESS | POSTER | #EHA2024 | Gaétan Basile @CHUBordeaux presents the efficacy and tolerance data for modified HCVAD-blinatumomab-TKI combination for relapsed/refractory ph+ b-cell #ALL. A high-rate of CR with MRD negativity was observed, however cardiovascular events and… pic.twitter.com/4QUOtJoSHE
— ALL Hub (@ALL_Hub_) June 14, 2024
CONGRESS | POSTER | #EHA2024 | @thomas_cluzeau @CHUdeNice reports results from the ATHENA study describing real-world utilization of blinatumomab in adult and pediatric patients with ALL in France. Four key uses of blinatumomab were identified: HSCT preparation, adults (31.3%),… pic.twitter.com/5gfrefaNJT
— ALL Hub (@ALL_Hub_) June 17, 2024
CONGRESS | POSTER | #EHA2024 | Victor Urbalejo shares findings from a retrospective analysis of blinatumomab in patients with ALL in Latin America (N=138). Blinatumomab elicited significant responses with good tolerability. #allsm #leusm #MedicalCongress pic.twitter.com/dSXhnywevF
— ALL Hub (@ALL_Hub_) June 17, 2024
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
On average, how many patients with B-cell acute lymphoblastic leukemia do you see in a year?